Table 1 Characteristics of patients who underwent HFNC therapy

Number (n)

56

Median age, years (range)

59 (24–82)

Sex (male/female)

38/18

Underlying hematological disease (n)

 AML

23

 ALL

9

 MDS

11

 CMML

2

 CMLBC

2

 ATLL

3

 NHL

3

 PLL

1

 ITP

1

 SAA

1

Disease risk^a (high/low)

33/23

Cause of ARF (n)

 Pneumonia

37

 Congestive heart failure

7

 Organized pneumonia

4

 Pulmonary chronic GVHD

2

 Leukemic pulmonary invasion

2

 Multiple organ failure

2

 No identifiable cause

2

Median number of WBC (/μL) at the onset of ARF (range)

1850 (10–398,300)

Neutropenia (<500/μL)at the onset of ARF (yes/no)

32/24

Median number of platelet at the onset of ARF (×10⁴/μL) (range)

2.8 (0.2–28.8)

Concomitant clinical condition

 Acute kidney injury^b (yes/no)

35/21

 Liver dysfunction^c (yes/no)

14/42

 Allogeneic hematopoietic stem cell transplantation (yes/no)

26/30

Past clinical history

 Cardiac disease^d (yes/no)

5/51

 Pulmonary disease^e (yes/no)

8/48

 Allogeneic hematopoietic stem cell transplantation (yes/no)

42/14

Median oxygen supplement volume before putting HFNC (L/min) (range)

10 (4–20)

HFNC setting

 Median FDO₂ (%) (range)

60 (30–100)

 Median flow (L/min) (range)

40 (15–60)

 Median time used (h) (range)

88 (1–950)